At present, there are about 84,000 new lymphoma patients in China every year, and the rate of increase is 5% per year. What is more serious is that in recent years, lymphoma has become more and more “favorable” to young people, and the incidence trend is becoming younger. When it comes to this systemic malignant disease involving the immune system, the first reaction of the majority of people is that the disease is equivalent to a terminal disaster. About 30% of lymphoma patients are difficult to treat The lymphatic system is an important defense system of the body and is often referred to as the human “guard”. However, lymphatic tissues can also get out of control of the body and become “bad elements”. When there are more and more “bad molecules” and factors such as bad environment, lymphocytes may mutate during the growth process and form crazy lymphoma. However, “lymphoma” is not a disease, but a group of malignant diseases with various manifestations and essences, which can be divided into two types: Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, with the latter accounting for about 90%. Among non-Hodgkin’s lymphoma, about 3% become diffuse large B-cell lymphoma. Compared with other types of lymphoma, these patients have faster tumor progression and higher malignancy, which can progress rapidly within six months to a year, making treatment more difficult. Although diffuse large B-cell lymphoma is difficult to treat, it does not mean that we are “helpless” to do so. Internationally, it has been reported that “immunotherapy (melphalan) combined with chemotherapy regimens are now significantly improving the outcome of patients with diffuse large B-cell lymphoma. Studies have shown that adherence to 8 courses of standard therapy resulted in complete tumor remission in 76% of patients, while a 10-year follow-up found that 58% of patients were cured and more than 40% of patients had 10-year long-term survival [4]. Don’t neglect regular review After completing the standard treatment regimen, can lymphoma patients rest on their laurels? The answer is no. Although after receiving standard treatment, patients’ disease is controlled and about 60% of patients are cured, patients will face a series of problems after treatment, such as physical and psychological recovery after anti-tumor therapy, potential long-term complications, and reintegration into family and society. Therefore, lymphoma patients need to be followed up every 3 months for the first 2 years after the end of treatment, and then once every 6 months to once a year for the rest of their lives, so as to ensure better survival.